GSK3B and neurodegenerative disease: Indeed, the specific GSK3β inhibitor has emerged as a therapeutic target for drug development for tau pathology in neurodegenerative disease [43], our studies thus broaden the theoretical basis for the treatment of neurodegenerative diseases with GSK3β inhibitors.